证券代码：688114 证券简称：华大智造 公告编号：2025-066 深圳华大智造科技股份有限公司 关于增加公司 2025 年度日常关联交易预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本事项需提交公司股东大会审议。 ●日常关联交易对公司的影响：因业务发展需要及采购需求增加，本次增加 日常关联交易预计额度事项属于公司日常经营活动需要，符合公司实际经营情况， 按照公平、公正、公开原则开展，遵循公允价格作为定价原则，不存在损害公司 及股东利益的情况，也不存在向关联方输送利益的情况，且不会影响公司独立性， 不会对关联方形成较大的依赖。 一、日常关联交易基本情况 （一）关于 2025 年度日常关联交易预计额度履行的审议程序 深圳华大智造科技股份有限公司（以下简称"公司"）于 2025 年 1 月 17 日召开了第二届董事会第十一次会议审议通过了《关于 2025 年度日常关联交易 额度预计的议案》。关联董事汪建、牟峰、徐讯、余德健、朱岩梅、吴晶已对此 议案回避表决。上述议案已经公司于 2025 年 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-065 深圳华大智造科技股份有限公司 关于取消监事会、修订《公司章程》并办理工商变更登记及 修订、制定部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳华大智造科技股份有限公司（以下简称"公司"）于 2025 年 10 月 22 日召开的第二届董事会第十八次会议审议通过了《关于修订〈公司章程〉并办理 工商变更登记的议案》及《关于修订、制定公司部分治理制度的议案》。现将相 关情况公告如下： 一、关于变更注册资本的情况 公司于 2024 年 10 月 16 日完成了 2020 年股票期权激励计划第三个行权期行 权结果的股份登记工作，本次行权的股票期权数量为 878,531 股，本次行权后， 公司总股本由 415,637,624 股变更为 416,516,155 股，注册资本由 415,637,624 元 变更为 416,516,155 元。 三、关于修订《公司章程》的情况 为进一步提升公司规范运作水平，根据《公司法》《上市公司章程指引（202 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-069 深圳华大智造科技股份有限公司 1 第二届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳华大智造科技股份有限公司（以下简称"公司"）第二届监事会第十七 次会议于 2025 年 10 月 22 日以现场结合通讯方式召开。会议通知已于 2025 年 10 月 19 日通过邮件的方式送达各位监事。本次会议应出席监事 3 人，实际出席 监事 3 人。会议由监事会主席周承恕先生主持。会议召开符合有关法律、行政法 规、部门规章和《公司章程》的规定。出席会议的监事对以下议案进行了认真审 议并做出了如下决议： 一、审议通过《关于增加公司 2025 年度日常关联交易预计额度的议案》 经审核，监事会认为：本次增加日常关联交易额度事项符合公司日常经营业 务实际需要，交易事项在关联各方平等协商的基础上按照市场价格的定价原则进 行，遵循了一般商业原则，交易定价公允，不存在损害公司及股东利益，特别是 中小股东利益的情形。关联董事对该议案依法进行了回 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-068 深圳华大智造科技股份有限公司 第二届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2024 年 10 月 16 日完成了 2020 年股票期权激励计划第三个行权期 行权结果的股份登记工作，本次行权后，公司股本及注册资本即发生变更；根 据《公司法》及相关法律、法规及规范性文件的规定，公司拟变更股本和注册 资本。 根据《公司法》《关于新〈公司法〉配套制度规则实施相关过渡期安排》《上 市公司章程指引》等相关法律法规、规范性文件的规定，结合公司实际情况， 公司拟取消监事会，监事会的职权由董事会审计委员会行使，基于此，公司相 应修订《公司章程》并办理工商变更备案登记。 1 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《关于取消监事会、修订〈公司章程〉并办理工商变更登记及修订、制定部分 治理制度的公告》（公告编号：2025-065）及修订后的《公司章程》。 表决结果：同意 10 票，反对 0 票 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥755,198,083.64, representing a year-on-year increase of 14.45%[4] - The total profit for the period was ¥17,009,441.48, while the net profit attributable to shareholders was -¥15,998,260.06, indicating a significant loss[4] - The total profit for the reporting period was positive, with a year-on-year improvement of 110.98%, primarily due to a 14.45% increase in operating revenue and significant cost reductions[11] - The net profit attributable to shareholders for the reporting period showed a year-on-year loss reduction of 74.20%, driven by cost efficiency measures and foreign exchange gains from USD and EUR fluctuations[11] - The net profit for the first three quarters of 2025 was -120,999,586.04 RMB, compared to -466,701,054.62 RMB in the same period of 2024, showing an improvement of approximately 74%[23] - The company reported a total comprehensive loss of -177,871,128.11 RMB for the first three quarters of 2025, compared to -479,109,602.25 RMB in the same period of 2024[24] Research and Development - Research and development (R&D) expenses totaled ¥122,858,816.78, a decrease of 38.94% compared to the same period last year, accounting for 16.27% of operating revenue[4] - Research and development expenditures decreased by 38.94% in the reporting period as the company focused on cost reduction and resource optimization[11] - Research and development expenses for the first three quarters of 2025 were CNY 383,291,057.44, down from CNY 553,504,354.12 in 2024, reflecting a decrease of about 30.8%[22] - The company is focusing on core projects and strengthening personnel and material management to optimize R&D spending[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,128,027,308.00, down 1.81% from the end of the previous year[5] - Current assets totaled CNY 6,380,724,974.77, down from CNY 6,514,349,633.15 at the end of 2024, representing a decline of approximately 2.0%[18] - The company's total liabilities were CNY 2,398,889,737.75, compared to CNY 2,423,155,396.08 in the previous year, indicating a decrease of about 1.0%[19] - The company’s total equity decreased to CNY 7,729,137,570.25 from CNY 7,891,700,329.82 year-over-year[20] Cash Flow - The company reported a net cash flow from operating activities of -¥288,729,045.45 for the year-to-date period[4] - The net cash flow from operating activities for the period decreased by 66.05% year-on-year, mainly due to increased sales collections[11] - Operating cash flow for the first three quarters of 2025 was -288,729,045.45 RMB, an improvement from -850,486,070.21 RMB in the first three quarters of 2024[26] - The company generated cash inflows from investment activities totaling 6,436,944,032.41 RMB in the first three quarters of 2025, compared to 645,134.92 RMB in the same period of 2024[27] - The net cash flow from financing activities for the first three quarters of 2025 was 240,774,491.80 RMB, compared to -24,810,163.70 RMB in the same period of 2024[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,418, with no preferred shareholders[13] - The largest shareholder, Shenzhen BGI Technology Holdings, held 153,001,440 shares, representing 36.73% of total shares[14] - The second-largest shareholder, Tibet Huazhan Venture Capital, held 41,442,948 shares, accounting for 9.95% of total shares[14] - CPE Investment (Hong Kong) Limited held 17,863,328 shares, representing 4.29% of total shares[14] - The company has not reported any significant changes in major shareholders or financing activities during the reporting period[16] Cost Management - The company has implemented strategies to enhance operational efficiency and reduce costs, contributing to improved financial performance[11] - Total operating costs decreased to CNY 1,995,858,843.93 from CNY 2,295,399,468.98 year-over-year, indicating a reduction of approximately 13.1%[22] - The company incurred a total operating expense of 2,672,097,429.46 RMB in the first three quarters of 2025, slightly down from 2,678,908,901.41 RMB in the same period of 2024[27] Investment Income - The company reported a net investment income of CNY 18,120,134.07 for the first three quarters of 2025, compared to a loss of CNY 1,908,278.03 in the same period of 2024[22] - The company reported a significant increase in investment income, receiving 20,300,742.88 RMB in the first three quarters of 2025, compared to 625,724.92 RMB in the same period of 2024[27]

华大智造公告，第三季度营收为7.55亿元，同比增长14.45%；净利润亏损1599.83万元。前三季度营收 为18.69亿元，同比下降0.01%；净利润亏损1.2亿元。 ...

Core Viewpoint - Shenzhen Guochuang Zhongke Medical Technology Co., Ltd. has signed a strategic cooperation agreement with BGI Genomics to enhance the development of consumer health management in China [1] Group 1: Company Collaboration - The collaboration will leverage BGI Genomics' Bloomics® single-use peripheral blood collection system [1] - Shenzhen Guochuang Zhongke will contribute its resources and experience in home testing [1] - The partnership aims to create a new model for health management in the consumer health sector [1]

Core Points - The Medical Health R Index (480016) closed at 7852.45 points, up 1.04%, with a trading volume of 22.052 billion yuan and a turnover rate of 0.74% [1] - Among the index constituents, 40 stocks rose while 9 fell, with WuXi AppTec leading the gainers at 4.27% and Pian Zai Huang leading the decliners at 0.91% [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (603259) with a weight of 14.37%, latest price at 102.04, and a market cap of 304.463 billion yuan [1] - Hengrui Medicine (600276) with a weight of 11.45%, latest price at 66.00, and a market cap of 438.055 billion yuan [1] - Mindray Medical (300760) with a weight of 8.07%, latest price at 223.57, and a market cap of 271.066 billion yuan [1] - United Imaging Healthcare (688271) with a weight of 4.32%, latest price at 143.03, and a market cap of 117.879 billion yuan [1] - Pian Zai Huang (600436) with a weight of 3.59%, latest price at 185.38, and a market cap of 111.843 billion yuan [1] - Aier Eye Hospital (300015) with a weight of 3.21%, latest price at 12.33, and a market cap of 114.982 billion yuan [1] - Kelun Pharmaceutical (002422) with a weight of 2.54%, latest price at 36.05, and a market cap of 57.610 billion yuan [1] - Changchun High & New Technology (000661) with a weight of 2.35%, latest price at 120.28, and a market cap of 49.067 billion yuan [1] - Fosun Pharma (600196) with a weight of 2.28%, latest price at 29.28, and a market cap of 78.190 billion yuan [1] - Sinopharm (002001) with a weight of 2.22%, latest price at 23.27, and a market cap of 71.519 billion yuan [1] Capital Flow Analysis - The net inflow of main funds into the Medical Health R Index constituents totaled 634 million yuan, while retail funds saw a net outflow of 105 million yuan [1] - Detailed capital flow for key stocks includes: - WuXi AppTec with a net inflow of 353.9 million yuan from main funds [2] - Sinopharm with a net inflow of 90.036 million yuan from main funds [2] - Hengrui Medicine with a net inflow of 76.418 million yuan from main funds [2] - Other stocks like Changchun High & New Technology and Fosun Pharma also experienced varying levels of net inflow and outflow [2]

（原标题：华大智造新设科技公司，含汽车销售业务） 企查查APP显示，近日，北京华大智造科技有限公司成立，法定代表人为倪培相，经营范围包含：汽车 零配件零售；汽车销售；新型膜材料销售；高性能密封材料销售；药物检测仪器销售；实验分析仪器销 等。企查查股权穿透显示，该公司由华大智造（688114）间接全资持股。 ...

人民财讯10月21日电，企查查APP显示，近日，北京华大智造科技有限公司成立，法定代表人为倪培 相，经营范围包含：汽车零配件零售；汽车销售；新型膜材料销售；高性能密封材料销售；药物检测仪 器销售；实验分析仪器销等。企查查股权穿透显示，该公司由华大智造间接全资持股。 ...